First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

被引：0
|
作者：
Camidge, D. Ross
Bazhenova, Lyudmila
Salgia, Ravi
Weiss, Glen J.
Langer, Corey J.
Shaw, Alice Tsang
Narasimhan, Narayana I.
Dorer, David J.
Rivera, Victor M.
Zhang, Joshua
Clackson, Tim
Haluska, Frank G.
Gettinger, Scott N.
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] UC San Diego Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Virginia G Piper Canc Ctr, Scottsdale Healthcare Program, Scottsdale, AZ USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] ARIAD Pharmaceut Inc, Cambridge, MA USA
[8] Yale Univ, Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8031
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
    Camidge, D. R.
    Bazhenova, L.
    Salgia, R.
    Weiss, G. J.
    Langer, C. J.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Zhang, J.
    Gettinger, S. N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S795 - S795
  • [2] UPDATED RESULTS OF A FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Weiss, Glen J.
    Langer, Corey J.
    Shaw, Alice T.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Zhang, Joshua
    Clackson, Tim
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S296 - S297
  • [3] A FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES
    Gettinger, S.
    Weiss, G. J.
    Salgia, R.
    Bazhenova, L.
    Narasimhan, N. I.
    Dorer, J.
    Rivera, V. M.
    Zhang, J.
    Clackson, T.
    Haluska, F.
    Shaw, A. T.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2012, 23 : 152 - 152
  • [4] Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [6] First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors.
    Kim, Yong Man
    Bae, Kyun-Seop
    Baek, Nam Seok
    Kim, Kyungun
    Lee, Won Sik
    Roh, Eun-Jihn
    Ock, Chan-Young
    Kim, Sung-Bae
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies
    Kuenen, BC
    Giaccone, G
    Ruijter, R
    Kok, A
    Schalkwijk, C
    Hoekman, K
    Pinedo, HM
    CLINICAL CANCER RESEARCH, 2005, 11 (17) : 6240 - 6246
  • [8] First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: Phase I dose-finding part results
    Yamamoto, Noboru
    Sato, Jun
    Kondo, Shunsuke
    Koyama, Takafumi
    Yonemori, Kan
    Iwasa, Satoru
    Shimizu, Toshio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [9] A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
    Lickliter, Jason D.
    Gan, Hui K.
    Voskoboynik, Mark
    Arulananda, Surein
    Gao, Bo
    Nagrial, Adnan
    Grimison, Peter
    Harrison, Michelle
    Zou, Jianjun
    Zhang, Lianshan
    Luo, Stacey
    Lahn, Michael
    Kallender, Howard
    Mannucci, Andrea
    Somma, Catello
    Woods, Katherine
    Behren, Andreas
    Fernandez-Penas, Pablo
    Millward, Michael
    Meniawy, Tarek
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1177 - 1189
  • [10] RESULTS OF A FIRST-IN-HUMAN PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN ADVANCED SOLID TUMORS
    Shaw, A. T.
    Camidge, D. R.
    Felip, E.
    Sharma, S.
    Tan, D. S. W.
    Kim, D.
    De Pas, T.
    Vansteenkiste, J. F.
    Santoro, A.
    Liu, G.
    Goldwasser, M.
    Dai, D.
    Boral, A. L.
    Mehra, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 153 - 153
12345